Dr. Suparno Chakrabarti

Program Director (Haemato-Oncology & BMT)
Senior Consultant & HOD (Haemato-Oncology & BMT)
MD (Internal Medicine, PGIMER, Chandigarh)
MD (Blood & Marrow Transplantation, University of Birmingham, UK)
Fellow of Royal College of Pathologists (Haematology, London, UK)
20+ Years of Experience

Brief Profile

Senior Consultant Haemato-oncologist and Program Director of Blood and Marrow Transplantation, Dharamshila Hospital and Research Centre

Specialized in Stem Cell transplantation, Bone Marrow Transplant, Cord Blood Transplant.

Dr. Suparno Chakrabarti was born in Kolkata (India) in 1964. He completed his post-graduation in Internal Medicine from PGIMER, Chandigarh in 1993 and left for CMCH, Vellore to train in Haematology and BMT. Dr. Chakrabarti returned to PGIMER after a year’s training in CMCH Vellore and was instrumental in setting up the department of CLINICAL HAEMATOLOGY. IN 1998, he left for the UK to undertake a fellowship in BMT at Birmingham Heartland’s Hospital and Bristol Children’s Hospital for 5 years. During this period his clinical and lab research in the field of BMT led to several breakthroughs such as in the field of post-transplant infections and reduced intensity transplantation and use of CAMPATH antibodies in transplant. With over 100 publications in the field and similar number of presentations in International meetings and conferences, he stands as a leading international figure in the field of haematology and BMT. As recognition of his contribution in this field, Dr. Chakrabarti was awarded the FELLOWSHIP of the ROYAL COLLEGE OF PATHOLOGISTS (Haematologists).

Dr. Chakrabarti had been the lead consultant in BMT at St George’s Hospital, London for several years. During this time, he was instrumental in setting up the Cord Blood Transplant Program in the unit. Following the successful use of Double-Cord Transplants in Minnesota, he initiated this program in his unit. He also made further contributions by innovating a tandem approach in transplanting patients with aplastic anemia transforming to leukaemia. Another major development was his revelation on the use of ATG in aplastic anemia pre-transplant and the risk of EBV-associated  lymphoproliferative disease post-transplant.

He has been invited worldwide to talk on these subjects and has been nominated in the expert committee for European and International Bone Marrow Transplant Organizations. He has been in the Editorial Committee of many international journals and acts as a reviewer for international cancer organizations.

In the honour of his late mother, Dr. Chakrabarti has set-up a charity for children suffering from BLOOD DISORDERS, the MANASHI CHAKRABARTI FOUNDATION. Having achieved all possible laurels in the field of BMT, Dr. Chakrabarti has left the job of heading the BMT unit at St George’s Hospital in London in order to provide this service to the people of West Bengal as he felt his services should now be dedicated to his own countrymen.

Positions and Employment

  • Consultant Hemato-Oncologist & and Program Director of Dept of Blood and Marrow Transplantation, Apollo Gleneagles Hospital, Kolkata, India(2009 - 2013)
  • Consultant Haematologist (Stem Cell Transplantation And Haemato-Oncology) & Honorary Senior Lecturer St. George's Hospital And Medical School, London, UK (2006-2009)
  • Consultant (Assistant Professor) in Clinical Haematology (Dept of Internal Medicine), PGIMER, Chandigarh, India (1997-1998)
  • Honorary Research Fellow and Bone Marrow Transplant Fellow (Hon SpR,), C.R.UK Institute for Cancer Studies, University of Birmingham, Heartlands Hospital NHS Trust and Bristol Children's Hospital, UK (1998-2002)
  • Consultant Haematologist, City Hospital, Birmingham, UK (2002-2003)
  • Specialist Registrar (Haematology), West Midlands, UK (2004-2005)

Other Experience and Professional Memberships

  • Member of the Working Party on Infectious Diseases of the European Blood and Marrow Transplantation Society
  • Member of the Expert Working Committee of CIBMTR on POST-TRANSPLANT INFECTION PREVENTION
  • International member of ASH (American Society of Haematology)
  • Member of BSH (British Society of Haematology) and BSBMT (British Society of Blood and Marrow Transplantation)
  • Member of Scientific Working Group on 'QoL and Symptoms' of European Hematology Association
  • Member of ASBMT (American Society of Blood and Marrow Transplantation)

Academic Highlights

  • Peer reviewer for several scientific journals including BLOOD, Bone Marrow Transplantation, Haematologica, British Journal of Haematology, Clinical Infectious Diseases, Biology of Blood and Marrow Transplantation, JAMA, Lancet etc.
  • Reviewer of grant proposals for AIRC (The Italian Association for the Search on the Cancer).
  • Invited speaker at Asia-Pacific BMT Congress2002, Asian Transplant Congress, 2002, & EBMT workshop Milan, 2004.
  • Editorial Board member for 'Current Stem Cell Research & Therapy (CSCRT) and several others
  • Expert panel member on post-transplant infections of the Centre for International Bone marrow Transplant Registry, USA.
  • Invited Guest Editor for several journals on special issues on Transplantation.
  • Invited Faculty at Scientific Session on Hematopoeitic Stem Cell Transplantation, HEMATCON 2010 and ISHTMPGI 2011 organised by Indian Society of Hematology and Transfusion Medicine.

Scientific Publications

  • Chakrabarti S, Singh K, Singh V, Nain CK, Jindal SK. Airway response to acid instillation in esophagus in bronchial asthma. Indian J Gastroenterol 1995; 14(2): 44-47.
  • Chakrabarti S, Behera D, Varma S, Bambery P. Methyl prednisolone in sarcoidosis associated thrombocytopenia. Sarcoidosis 1997; 14: 188.
  • Chakrabarti S, Varma S, Singh S, Kumari S. Low dose amino caproic acid : an alternative to platelet transfusion in thrombocytopenia. European Journal of Haematology 1998; 60(5): 313-314.
  • Chakrabarti S, Varma S, Kochhar R, Rajwanshi A, Gupta S.Hepatosplenic tuberculosis: a cause for persistent fever in recovering neutropenia. Int. J. Tuberculosis and Lung Dis 1998; 2(7):575-579.
  • Chakrabarti A; Varma N; Kumar B; Chakrabarti S; Varma S. Dyskeratosis congenita: DNA repair defect ?. Indian Journal of Hematology and Blood Transfusion. 1998 Mar.; 16(1): 34-7
  • Chakrabarti S, Collingham K, Fegan CD, Milligan DW: Fulminant adenvirus hepatitis following unrelated donor bone marrow transplant: failure of ribairin therapy. Bone Marrow Transplant 1999; 23: 1209-1211.
  • Chakrabarti S, Collingham K, R H Stevens, Fegan CD, Milligan DW: Isolation of viruses from stools in stem cell transplant recipients. Bone Marrow Transplant 2000; 25; 277-282.
  • Chakrabarti S, Pillay D, Ratcliffe D, Cane P, Collingham K, Milligan DW: Herpes Simplex Virus Infections in stem cell transplant recipients: significance of antiviral resistance and its prognostic significance. Journal of Infectious Disease 2000; 181: 2055-2058.
  • Chakrabarti S, Collingham K, Fegan CD, Milligan DW. Adenovirus infections following stem cell transplantation: is there a role for adoptive immunotherapy. Bone Marrow Transplant 2000; 26(3): 305-307.
  • Kottaridis PD, Milligan D W, Chopra R, Chakraverty RK, Chakrabarti S et al. In vivo Campath 1H prevents graft-versus-host disease following non-myeloablative stem cell transplantation. Blood 2000; 96(7): 2419-25.
  • Chakrabarti S, Lees A, Jones S, Milligan DW. Clostridium difficile infection in stem cell transplant recipients is associated with severe graft versus host disease and non-relapse mortality. Bone Marrow Transplant 2000;26:871-876.
  • Chakrabarti S, Collingham K, Pillay D, Holder K, Milligan DW. Parainfluenza virus infection after BMT: response to ribavirin. Clin Infectious Disease 2000;26:1516-1518 .
  • Chakrabarti S, Handa S, Bryon RJ, Grifiths M, Milligan DW. Will mixed chimerism cure autoimmune diseases after a nonmyeloablative stem cell transplant. Transplantation 2001; 72: 340-342.
  • Chakrabarti S, Alsop A, Sepphard S et al. Establishment of a community-based autologous blood stem cell service in UK: a pilot study. British Journal of Intensive Care 2001; 11: 51-56.
  • Robertson JD, Testa NG, Russell NH, Jackson G, Parker AN, Milligan DW, Stainer C, Chakrabarti S, Dougal M and Chopra R. Accelerated telomere shortening following allogeneic transplantation is independent of the cell source and occurs within the first year post transplant. Bone Marrow Transplant 20001; 27: 1283-1286.
  • Chakrabarti S, McDonald D, Milligan DW. T cell depleted nonmyeloablative transplantation: What is the optimum balance between the intensity of host-conditioning and degree of T cell depletion? (letter).Bone Marrow Transplant 2001: 28; 313-314.
  • Chakrabarti S, Collingham K, Fegan CD, Milligan DW. Respiratory viral infections in adult T cell depleted stem cell transplants: the role of cellular immunity. Transplantation 2001; 72: 1460-63.
  • Chakraverty R, PeggsK, Chopra R, Milligan D, Kottaridis P, Verfuerth P, Geary J, Thuraisundaram D, Branson K, Chakrabarti S et al. Limiting transplant-related mortality following unrelated donor stem cell transplantation by using a non-myeloablative conditioning regimen. Blood 2001;99: 1071-78.
  • Chakrabarti S, Collingham K E, Holder K, Fegan CD, Osman H, Milligan D W Pre-emptive therapy of paramyxovirus infections after haematopoetic stem cell transplantation with oral ribavirin: a pilot study. Bone Marrow Transplant 2001;28:759-763.
  • Milligan D, Chakrabarti S. Parainfluenza virus infections in stem cell transplant recipients. In Respiratory Virus infections; Not just a snuffly nose, October, 2001 (pub: eurocommunications).
  • Chakrabarti S, Collingham K E, Fegan CD, Osman H, Milligan D W. Cidofovir as primary pre-emptive therapy for post-transplant cytomegalovirus infections. Bone Marrow Transplant 2001;28:759-763.
  • Kottaridis PD, Milligan D W, Chopra R, Chakraverty RK, Chakrabarti S et al. In vivo Campath 1H prevents graft-versus-host disease following non-myeloablative stem cell transplantation. Cytotherapy 2001; 3:197-201.
  • Chakrabarti S. Critical factors in optimising graft-versus-leukaemia effect for relapsed acute leukemia (letter). Journal Clin Oncol 2002; 20:2756
  • Chakrabarti S. The place of rituximab in the treatment algorithm of post-SCT auto-immune hemolytic anemia. Haematologica 2002; 87 (ELT 2)
  • Chakrabarti S, Mackinnon S, Chopra R et al. High incidence of CMV reactivation after nonmyeloablative transplants: potential role of CAMPATH-1H in delayed immune recovery. Blood 2002; 99: 4357-63.
  • Chakrabarti S et al. Adenovirus infections in Stem cell transplant recipients: the incidence and outcome in relation to graft manipulation, immunosuppression and immune reconstitution. Blood 2002; 100: 1619-1627.
  • Rymes NL, Lester W, Connor C, Chakrabarti S, Fegan CD. Outpatient management of DVT using low molecular weight heparin and a hospital outreach service. Clin Lab Haematol 2002; 24:165-170.
  • Chakrabarti S et al. Respiratory Virus Infections In Transplant Recipients After Reduced Intensity Conditioning With CAMPATH-1H: High Incidence But Low Mortality. British Journal of Haematology 2002;119: 1125-32
  • Chakrabarti S. Non-herpes viral infections and anti-viral immunity after stem cell transplantation. Transplant proceedings 2002; 35: 509-510
  • Chakrabarti S. The relevance of nonmyeloablative transplantation in developing countries: the lessons from the UK experience. Transplant proceedings 2002; 35: 172-173
  • Chakrabarti S Increased CMV Infection Following Nonmyeloablative Allogeneic Stem Cell Transplantation: A Search For The Guilty. Blood (letter) 2003: 101; 2071.
  • Cane P, van der Hoogan BG, Chakrabarti S, Fegan C, Osterhaus AD. Human metapneumovirus in a haematopoietic stem cell transplant recipient with fatal lower respiratory tract disease. Bone Marrow Transplant 2003 Feb;31(4):309-10
  • Chakrabarti S et al. Polyoma viruria in stem cell transplant recipients T cell depleted with Campath-1H: the incidence and outcome in relation to graft manipulation, donor type and conditioning. Bone Marrow Transplant 2003 Mar;31(5):379-86
  • Chakrabarti S, MacDonald M, Hale G et al. T cell depletion with Campath-1H in the bag for matched related peripheral stem cell transplantation is associated with low incidence of GVHD, rapid immune recovery and improved survival. British Journal of Haematology 2003 Apr;121(1):109-18
  • Chakrabarti S et al,. Early Lymphocyte Recovery Is An Important Determinant Of Outcome Following Allogeneic Transplantation with CD34+ Selected Graft And Limited T Cell Addback. Bone Marrow Transplantation 2003; 32: 23-30.
  • Chakrabarti S, Milligan D, Pillay D. Reconstitution of Epstein-Barr-Virus-Specific Cytotoxic T Lymphocyte Response Following T-Cell Depleted Myeloablative and Non-Myeloablative Allogeneic Stem Cell Transplantation. Blood 2003 Aug 1;102(3):839-42
  • Chakrabarti S, Marks DI. Should we T cell deplete sibling grafts for AML in CR-1 (Review). Bone Marrow Transplant. 2003;32(11):1039-50.
  • Chakrabarti S, Mautner V et al. Adenovirus infections in stem cell transplant recipients (invited review). Leuk Lymphoma 2004; 45: 873-885.
  • Chakrabarti S et al. Influence Of Cytomegalovirus (CMV) Sero-Positivity On CMV Infection, Lymphocyte Recovery And Non-CMV Infections Following T Cell Depleted Allogeneic Stem Cell Transplantation:A Comparison Between Two T Cell Depletion Regimens. Bone Marrow Transplantation Bone Marrow Transplant. 2004;33(2):197-204.
  • Chakrabarti S and Bareford D. Will The Developments In Allogeneic Transplantation Influence Management Of Adult Patients With Sickle Cell Disease? (Review)Biology of Blood and Marrow Transplantation Biol Blood Marrow Transplant. 2004 Jan;10(1): 23-31.
  • Chakrabarti S, Osman H, Collingham K et al. Enterovirus infections following T-cell depleted Allogeneic transplantation in adults. Bone Marrow Transplant. 2004 Feb;33(4):425-30
  • Avivi I, Chakrabarti S et al. Incidence and outcome of adenovirus disease following alemtuzumab-based reduced intensity allogeneic transplantation. Biology of Blood and Marrow Transplantation. 2004 Mar;10(3):186-94.
  • Lahteenmaki PM, Chakrabarti S et al. Outcome of single fraction total body irradiation-conditioned stem cell transplantation in younger children with malignant disease--comparison with a busulphan-cyclophosphamide regimen.? Acta Oncol. 2004;43(2):196-203.
  • Avivi I, Chakrabarti S et al. Neurological complications following alemtuzumab-based reduced intensity allogeneic transplantation. Bone Marrow Transplantation 2004 ; 34(2):137-42
  • Chakrabarti S, Hale G, Waldmann H. Alemtuzumab in allogeneic stem cell transplantation: where do we go from here. Tranplant Proceedings. 2004; 36:1225-7.
  • Karanth M, Chakrabarti S et al. A Randomised Study Comparing Peripheral Blood Progenitor Mobilisation Using Intermediate Dose Cyclophosphamide Plus Lenograstim With Lenograstim Alone. Bone Marrow Transplantation 2004; 34: 399-403.
  • Aleem A, Lovell R, Holder K, Chakrabarti S et al. Performing bone marrow harvest on an outpatient basis: a single center UK experience. Acta Haematol. 2004;112(4):200-2.
  • Chakrabarti S. Alemtuzumab in-vivo or in-vitro: the impact on infections, relapse and immune reconstitution. Proceedings of the 3rd workshop of EBMT, October, 2004.
  • Cohen J, Cooper N, Chakrabarti S et al. EBV-related disease following hematopoietic stem cell transplantation with reduced intensity conditioning. Leuk Lymphoma (invited review).
  • Chakrabarti S. Nonmyeloablative Allogeneic Stem Cell Transplantation: Achievements, Failures And The Future. Current Stem cell Research (invited review).
  • Chakrabarti S and Bareford D. A Survey on Patients' Perception of Reduced Intensity Transplantation in Adults with Sickle Cell Disease. Bone Marrow Transplant. Bone Marrow Transplantation 2007; 39: 447 - 451.
  • Chakrabarti S. Bone Marrow Transplantation: a potential cure neglected? News Review of Sickle Cell Society, Spring 2007. 53.Chakrabarti S. Adenovirus infections after hematopoietic stem cell transplantation: still unravelling the story. Clin Infect Dis 2007; 45(8):966-968. (Editorial Commentary)
  • Anoop P, Bevan DH, Chakrabarti S. Usefulness and limitations of Bayesian network model as a mortality risk assessment tool in sickle cell anemia. Am J Hematol. 2009 May;84(5):312-3.
  • Buyck HC, Holliman R, Else J, O'Regan L, Willis F, Grubnic S, Marsh J, Chakrabarti S. An unusual cause of acute abdomen following allogeneic transplantation: a zoonotic disease revisited.. Bone Marrow Transplant. 2008 Jun;41(12):1069-70.
  • Buyck HC, Ball S, Junagade P, Marsh J, Chakrabarti S. Prior immunosuppressive therapy with antithymocyte globulin increases the risk of EBV-related lymphoproliferative disorder following allo-SCT for acquired aplastic anaemia. Bone Marrow Transplant. 2009 May;43(10):813-6
  • Zaia J, Baden L, Boeckh MJ, Chakrabarti S, Einsele H, Ljungman P, McDonald GB, Hirsch H; Center for International Blood and Marrow Transplant Research; National Marrow Donor Program; European Blood and Marrow Transplant Group; American Society of Blood and Marrow Transplantation; Canadian Blood and Marrow Transplant Group; Infectious Disease Society of America; Society for Healthcare Epidemiology of America; Association of Medical Microbiology and Infectious Diseases Canada; Centers for Disease Control and Prevention.Viral disease prevention after hematopoietic cell transplantation. Bone Marrow Transplant. 2009 Oct; 44(8):471-82
  • Chakrabarti S. Prevention and Treatment of Hepatitis virus infections in Hematopoietic StemCell Transplant Recipients.Medit J Hemat Infect Dis 2009, 1: DOI 10.4084/MJHID.2009.
  • Chakrabarti S. How do you treat secondary Iron Overload? Disorders of Iron Homeostasis. 2010. Edited by Ghosh MK et al. Chapter 20.
  • Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant. 2009 Oct;15(10):1143-238.
  • Chakrabarti S. Thalassemia in Developing World: care or Cure. Annals of Inst of Child Health, 2010; 10 (1): 12-17.
  • Chakrabarti S. When matched family donor is not available for blood and marrow transplantation- the Indian dilemma. Apollo Medicine, 2012;9: 62-67.

Invited Presentations

  • Chakrabarti S. Preemptive versus prophylactic treatment of CMV infections after allogeneic stem cell transplant. Northern BMT Consortium, Feb 1999, Nottingham.
  • Chakrabarti S. Nonmyeloablative Transplantation: the Heartlands experience. Northern BMT Consortium, June1999, Liverpool.
  • Chakrabarti S. Adenovirus infections in Stem cell transplant recipients. Northern BMT Consortium, June 2000, Leeds.
  • Chakrabarti S l. Herpes Simplex Virus Infections in stem cell transplant recipients: significance of antiviral resistance and its prognostic significance. 41st Annual meeting of American Society of Haematology, 1999, New Orleans and 26th Annual meeting of the European BMT group, 2000, Innsbruck.
  • Invited participant at the workshop on Haploidentical transplantation, Perugia. October 2000.
  • Chakrabarti S. High incidence of early and late CMV reactivation and delayed immune reconstitution after allogeneic transplants with nonmyeloablative conditioning using Campath (anti-CD52 antibody). 42nd Annual meeting of American Society of Haematology,200, San Francisco.
  • Chakrabarti S. Adenovirus infections in Stem cell transplant recipients. 28th Annual meeting of the European BMT group, 2002, Montreux.
  • Chakrabarti S. Polyoma viruria following T cell depleted transplants using Campath -1H: high incidence but low morbidity. 28th Annual meeting of the European BMT group, 2002, Montreux.
  • Chakrabarti S. T cell depleted transplants from related and unrelated donors using Campath -1H: low incidence of acute and chronic GVHD. 28th Annual meeting of the European BMT group, 2002, Montreux.
  • Chakrabarti S. Adenovirus infections in Stem cell transplant recipients: relation to immunosuppression and immune reconstitution. 150th general meeting of Society for General Microbiology, Warwick, UK
  • Chakrabarti S. The relevance of nonmyeloablative transplantation in developing countries: the lessons from the UK experience. Symposium at 7th Asian Transplant Congress, New Delhi, 2002.
  • Chakrabarti S. Non-herpes viral infections and anti-viral immunity after stem cell transplantation. Symposium at 7th Asian Transplant Congress, New Delhi, 2002.
  • Chakrabarti S. T cell depleted transplantation in AML. Asia-Pacific BMT Congress from 30 Oct- 3 Nov, 2002, Mumbai, India.
  • Chakrabarti S. Viral infections following allogeneic SCT. Asia-Pacific BMT Congress from 30 Oct- 3 Nov, 2002, Mumbai, India.
  • Chakrabarti S. Nonmyeloablative transplantation: current controversies. Asia-Pacific BMT Congress from 30 Oct- 3 Nov, 2002, Mumbai, India.
  • Chakrabarti S. Alemtuzumab in-vivo or in-vitro: the impact on infections, relapse and immune reconstitution. Invited speaker at the 3rd workshop of EBMT on New Perspectives in allogeneic transplantation; Milan, 2004.
  • Chakrabarti S. A Survey On Patients' Perception Of Reduced Intensity Transplantation In Adults With Sickle Cell Disease. 30th Annual meeting of the European BMT group, 2005, Prague.
  • Chakrabarti S. Umbilical Cord Blood Transplantation: An Indian Perspective. Symposium on Recent trends in virology and Immunohematology, Kolkata, India 2009.
  • Chakrabarti S. Umbilical Cord blood transplant: current perspective & future prospect. New Frontiers In Haematology And Oncology, Kolkata, India, 2010
  • Chakrabarti S. "Viral infections in HSCT Recipients and their Management" 51st National Conference of the Indian Society of Haematology & Transfusion Medicine in Kolkata, India, November, 2010
  • Chakrabarti S "Late effects in patients after BMT/SCT".EUROPEAN HEMATOLOGY ASSOCIATION Scientific Working Group; QUALITY OF LIFE AND SYMPTOMS, 3th of April, 2011, Paris, France.
  • Chakrabarti S 'Cyclophosphamide or Fludarabine or Campath in the conditioning regimen' 52nd Annual conference of Indian Society of Hematology and Blood Transfusion, Chandigarh, India November 2011 23.
  • Chakrabarti S et al. Haploidentical T-replete PBSC transplantation with reduced-intensity aplastic phase conditioning and post-transplantation cyclophosphamide for refractory myeloid leukaemias: a pilot study.

Post Your Query